학술논문
Conversion from cilostazol to OPC‐13015 linked to mitigation of cognitive impairment
Document Type
Report
Author
Source
Alzheimer’s & Dementia: Translational Research & Clinical Interventions. May 2021, Vol. 7 Issue 1
Subject
Language
English
Abstract
BACKGROUND Alzheimer's disease (AD) is the most common type of dementia and is characterized by neuropathological changes such as extracellular amyloid beta (Aβ) plaques and intracellular tau tangles. An excess [...]
: Introduction: Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. Methods: We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly prescribed. Patients underwent the Montreal Cognitive Assessment (MoCA) twice, at a 6‐month interval. Plasma cilostazol, OPC‐13015, OPC‐13213, and OPC‐13217 concentrations were determined using liquid chromatography‐tandem mass spectrometry. Results: MoCA score changes from baseline to the 6‐month visit were positively correlated with ratios of OPC‐13015 to cilostazol and total metabolites (n = 19, P =.005). Patients with higher ratios of OPC‐13015 (≥0.18, median value; n = 10) had significantly higher MoCA scores (P =.036) than patients with lower ratios (the ratio Discussion: Blood OPC‐13015 levels may be a predictive biomarker of cilostazol treatment for Alzheimer's disease.
: Introduction: Cilostazol may be a novel therapeutic agent for Alzheimer's disease. Its metabolite, OPC‐13015, has a stronger inhibitory effect on type 3 phosphodiesterase than cilostazol. Methods: We prospectively enrolled patients with mild cognitive impairment to whom cilostazol was newly prescribed. Patients underwent the Montreal Cognitive Assessment (MoCA) twice, at a 6‐month interval. Plasma cilostazol, OPC‐13015, OPC‐13213, and OPC‐13217 concentrations were determined using liquid chromatography‐tandem mass spectrometry. Results: MoCA score changes from baseline to the 6‐month visit were positively correlated with ratios of OPC‐13015 to cilostazol and total metabolites (n = 19, P =.005). Patients with higher ratios of OPC‐13015 (≥0.18, median value; n = 10) had significantly higher MoCA scores (P =.036) than patients with lower ratios (the ratio Discussion: Blood OPC‐13015 levels may be a predictive biomarker of cilostazol treatment for Alzheimer's disease.